List of Folotyn drug patents

Folotyn is owned by Acrotech.

Folotyn contains Pralatrexate.

Folotyn has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Folotyn are:

  • US6028071

Folotyn was authorised for market use on 24 September, 2009.

Folotyn is available in solution;intravenous dosage forms.

Folotyn can be used as treatment of patients with relapsed or refractory peripheral t-cell lymphoma.

The generics of Folotyn are possible to be released after 31 May, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6028071 ACROTECH Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
Jul, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299078 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

US7622470 ACROTECH Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
May, 2025

(2 years from now)

Drugs and Companies using PRALATREXATE ingredient

Market Authorisation Date: 24 September, 2009

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of FOLOTYN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic